LOGIN
ID
PW
MemberShip
2024-10-22 10:17
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Tevimbra may be prescribed in general hospitals in KOR
by
Eo, Yun-Ho
Sep 2, 2024 05:48am
The immuno-oncology drug 'Tevimbra' may now be prescribed in general hospitals in Korea. According to industry sources, BeiGene Korea's PD-1 inhibitor Tevimbra (tiselizumab) has passed the drug committees (DCs) of tertiary hospitals, including Samsung Medical Center and Seoul National University Hospital. In addition, the company succe
Company
API competition¡è with entry of Chinese and Indian pharmas
by
Son, Hyung-Min
Aug 30, 2024 05:50am
Chinese and Indian companies developing active pharmaceutical ingredients (APIs) are accelerating their entry into Korea. Numerous Chinese and Indian companies as well as domestic companies participated in 'CPHI Korea 2024,' an exhibition for the global pharmaceutical, bio, and health functional food industry that was held at COEX in Samseong-do
Company
Anti-cancer drug trends changes from IV¡æSC
by
Moon, sung-ho
Aug 30, 2024 05:50am
Global pharmaceutical companies speed up the development of subcutaneous (SC) formulations of their proprietary intravenous (IV) medications. To overcome the disadvantage of IV formulation medications that have long administration duration, more anti-cancer drugs are shifting to SC formulations. Following the trend, Korean companies with SC
Company
K-bio jumps into developing new drugs for pancreatic cancer
by
Son, Hyung-Min
Aug 30, 2024 05:50am
Korean pharmaceutical and biotech companies have jumped into the development of new drugs for pancreatic cancer, which is categorized as refractory cancer. Prestige Biopharma, New Cancer Cure Bio (NCC-Bio), LigaChem Biosciences, and Aptamer Sciences are conducting clinical trials to challenge the field. These companies plan to investigate the co
Company
Korean pharma and biotechs expand R&D investments
by
Chon, Seung-Hyun
Aug 29, 2024 04:32am
Listed pharma and biotech companies have expanded their research and development (R&D) investments in Korea this year. 3 out of 5 major pharmaceutical companies increased their R&D investments from last year to discover new candidates. Pharmaceutical companies with larger sales have been more active in reinvesting in R&D. According to the Fin
Company
Breast cancer drug Trodelvy receives DREC deliberations
by
Eo, Yun-Ho
Aug 29, 2024 04:31am
The ADC breast cancer drug Trodelvy has made a step toward insurance reimbursement after 9 months of wait. Gilead Sciences' triple-negative breast cancer (TNBC) drug Troldelvy, whose reimbursement request received 100,000 consents in a public petition, will be presented for deliberation to the Health Insurance Review and Assessment Servic
Company
"Switching of atopic dermatitis treatments not yet allowed"
by
Hwang, Byung-woo
Aug 28, 2024 05:52am
As new drug entries shift the market for atopic dermatitis, the public onion demands changes to reimbursement assessment, such as considering the comprehensive factors to use increased treatment options efficiently. Opinions have been suggested to consider factors related to patient quality of life, such as improving itchiness, in addition to
Company
K-made Leclaza monotherapy to be showcased at global meeting
by
Son, Hyung-Min
Aug 28, 2024 05:52am
Korean biopharmaceutical companies continue to gain R&D achievements for targeted anti-cancer drugs. Companies have prepared to present their Korean-made anti-cancer drugs, including Leclaza and Rivoceranib at the 2024 World Conference on Lung Cancer, which will be held September 7-10 in San Diego, USA. Yuhan Pharmaceutical will present
Company
Challenges in the evolving lung cancer treatment landscape
by
Son, Hyung-Min
Aug 28, 2024 05:51am
The head-to-head battle between the epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer drugs (NSCLC) Leclaza and Tagrisso has carried on to competition of each drug's combination therapy regimens. This month, the U.S. Food and Drug Administration (FDA) approved Leclaza+Rybrevant as a first-line treatment for EGFR-positive
Company
Value of new drugs should be evaluated based on efficacy
by
Hwang, Byung-woo
Aug 27, 2024 05:50am
'Receiving recognization of the value of new drugs' is one of the key challenges for pharma and biotech companies. With the proportion of new drugs being introduced into Korea rising and the number of homegrown new drugs increasing, the need for a drug pricing policy that recognizes the value of these new drugs has been growing. Recog
1
2
3
4
5
6
7
8
9
10
>